Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:58:46 2024-05-31 pm EDT			5-day change	1st Jan Change
2.3 ^USD	+6.98%		+9.52%	-65.85%

May. 08	Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	CI
May. 06	Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	MT

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.

May 07, 2024

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million on April 23, 2024.

Sentynl Therapeutics, Inc completed the acquisition of Global rights to Zokinvy from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million on May 3, 2024.

Latest news about Eiger BioPharmaceuticals, Inc.

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	May. 07	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	May. 06	MT
Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer	May. 02	CI
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer	May. 02	CI
Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	Apr. 24	CI
Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.	Apr. 19	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	Apr. 09	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Bidding Procedure Approved for Eiger BioPharmaceuticals, Inc.	Apr. 05	CI
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.	Apr. 05	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index	Apr. 03	CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	Apr. 03	CI
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET	Apr. 02	DJ
News Highlights : Top Company News of the Day - Monday at 11 PM ET	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET	Apr. 01	DJ
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 5 PM ET	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 7 PM ET	Apr. 01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
News Highlights : Top Company News of the Day - Monday at 3 PM ET	Apr. 01	DJ
Top Midday Decliners	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	Apr. 01	MT
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI

Chart Eiger BioPharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. The avexitide is a GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, Peginterferon Lambda (lambda) for COVID-19, Avexitide for Congenital Hyperinsulinism (HI) and Avexitide for Post-Bariatric Hypoglycemia (PBH). LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EIGER BIOPHARMACEUTICALS, INC.	-65.85%	3.41M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research

Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.

Latest news about Eiger BioPharmaceuticals, Inc.

Chart Eiger BioPharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research